| Name | Title | Contact Details |
|---|
Price Forbes is an independent insurance broker established in 1893 and headquartered in London. As part of Ardonagh Specialty, it is recognized as a leading broker in the London market. The company has a global presence, with offices worldwide, and specializes in wholesale insurance broking, focusing on complex risk management solutions for large multinational companies. The services offered by Price Forbes include specialist insurance broking, risk management, and reinsurance solutions through its division, Price Forbes Re. This division provides tailored reinsurance broking, capital solutions, and strategic advisory services, utilizing analytics to meet client needs. Price Forbes also has a strong presence in Africa, with operations in South Africa and partnerships across sub-Saharan Africa. In addition to its business activities, Price Forbes is committed to community involvement through the Ardonagh Community Trust, supporting charitable initiatives and contributing over £1.5 million to various causes.
Covenant reimagines the client experience to make life easier. Covenant is a specialized law firm focused on private market investors. We employ AI-powered software to provide the same high quality analysis as legacy legal work.
Based in North Carolina, the partnership of UNX and Christeyns brings together more than 100 years of experience in the textile care industry. Specializing in commercial quality cleaning chemicals for the laundry, housekeeping, warewashing, and dry and wet cleaning markets, these products are supported with custom designed dispensing equipment to produce high efficiency results for customers. Learn more by calling 800-869-6171 for more information or by visiting our website.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.